Tag: HCM

(CercleFinance.com) – Bristol Myers Squibb announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic hypertrophic obstructive…